PubRank

Andreas von Deimling

Author PubWeight™ 324.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012 10.99
2 Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003 8.06
3 Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008 7.79
4 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009 7.73
5 Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012 6.71
6 Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012 6.07
7 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
8 Dissecting the genomic complexity underlying medulloblastoma. Nature 2012 4.77
9 An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011 4.63
10 Long-term survival with glioblastoma multiforme. Brain 2007 4.51
11 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009 4.32
12 K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012 4.00
13 Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011 3.66
14 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009 3.65
15 Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014 3.52
16 High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012 3.44
17 Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009 3.38
18 FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011 3.33
19 International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014 3.21
20 Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011 3.11
21 Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2009 2.77
22 Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010 2.71
23 Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011 2.53
24 Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013 2.50
25 Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013 2.42
26 Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013 2.32
27 Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010 2.27
28 Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2006 2.22
29 Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008 2.21
30 Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest 2002 2.09
31 Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012 2.09
32 Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011 2.07
33 Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013 1.98
34 Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009 1.93
35 Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2011 1.91
36 Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011 1.90
37 The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2005 1.89
38 TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010 1.83
39 Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol 2010 1.82
40 Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013 1.80
41 A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol 2007 1.77
42 Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009 1.71
43 Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 2013 1.68
44 ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2014 1.66
45 Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010 1.65
46 Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 2011 1.61
47 Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002 1.61
48 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013 1.58
49 Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013 1.52
50 Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 2010 1.52
51 Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. Ann Thorac Surg 2009 1.49
52 Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013 1.49
53 HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010 1.46
54 A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab 2006 1.46
55 Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013 1.43
56 PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 2005 1.43
57 Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014 1.42
58 Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A 2010 1.41
59 BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012 1.36
60 Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015 1.35
61 TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013 1.35
62 Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009 1.34
63 Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010 1.34
64 Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010 1.32
65 Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 2010 1.32
66 Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006 1.32
67 Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol 2011 1.32
68 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2011 1.31
69 CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012 1.31
70 Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 2011 1.27
71 Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012 1.26
72 R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol 2010 1.22
73 Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 2012 1.22
74 Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neurosci Lett 2002 1.21
75 Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol 2008 1.20
76 mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A 2013 1.20
77 Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One 2012 1.19
78 Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012 1.19
79 Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics 2005 1.18
80 Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2006 1.18
81 Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013 1.17
82 Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 2007 1.17
83 Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013 1.17
84 BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013 1.16
85 Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 2009 1.16
86 Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015 1.16
87 Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013 1.15
88 Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012 1.15
89 BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013 1.14
90 IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015 1.13
91 Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013 1.13
92 Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 2004 1.13
93 Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 2008 1.12
94 LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 2012 1.12
95 Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002 1.11
96 Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2005 1.11
97 Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 2014 1.11
98 The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2011 1.10
99 Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012 1.09
100 TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res 2014 1.08
101 Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol 2012 1.08
102 Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011 1.08
103 Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2012 1.08
104 MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 2007 1.07
105 Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 2010 1.07
106 Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol 2003 1.07
107 Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 2009 1.06
108 Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst 2013 1.06
109 Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One 2012 1.05
110 RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 2008 1.05
111 Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 2008 1.04
112 Pathology and molecular genetics of oligodendroglial tumors. J Mol Med (Berl) 2004 1.04
113 Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003 1.04
114 A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 2011 1.04
115 EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 2008 1.03
116 Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol 2011 1.03
117 Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 2007 1.03
118 Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol 2004 1.03
119 AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 2013 1.03
120 Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol 2009 1.02
121 Interlaboratory comparison of IDH mutation detection. J Neurooncol 2013 1.02
122 Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys 2010 1.01
123 Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma 2006 1.00
124 Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015 0.99
125 Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011 0.99
126 Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 2009 0.98
127 Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Arch Pathol Lab Med 2013 0.98
128 No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 2012 0.97
129 Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 2011 0.97
130 Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 2006 0.97
131 The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Mol Cancer Ther 2008 0.97
132 Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 2015 0.97
133 Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest 2015 0.97
134 IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 2012 0.97
135 PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 2009 0.97
136 Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 2008 0.96
137 Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol 2014 0.96
138 BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 2014 0.96
139 Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2014 0.95
140 Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology 2014 0.95
141 The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. Genes Chromosomes Cancer 2002 0.94
142 Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am J Surg Pathol 2013 0.94
143 NF2 mutations in secretory and other rare variants of meningiomas. Brain Pathol 2006 0.93
144 Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol 2011 0.93
145 Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett 2006 0.93
146 A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS One 2013 0.93
147 Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 2013 0.92
148 Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012 0.92
149 The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 2013 0.92
150 Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011 0.92
151 Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010 0.92
152 Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014 0.92
153 DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Brain Pathol 2007 0.91
154 Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun 2015 0.91
155 Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 2014 0.91
156 Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 2011 0.91
157 Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004 0.91
158 Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. Acta Neuropathol Commun 2013 0.91
159 Gene regulation by methylation. Recent Results Cancer Res 2009 0.90
160 Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol 2013 0.90
161 Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. J Neuropathol Exp Neurol 2002 0.90
162 The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. PLoS One 2011 0.90
163 The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. Eur J Cardiothorac Surg 2010 0.90
164 IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica 2010 0.90
165 Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol 2013 0.89
166 Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. Genes Chromosomes Cancer 2005 0.89
167 Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer 2006 0.89
168 The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. PLoS One 2010 0.88
169 Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013 0.88
170 Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 2005 0.88
171 Hereditary tumor syndromes and gliomas. Recent Results Cancer Res 2009 0.88
172 Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy. Neuropathology 2007 0.87
173 GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 2014 0.87
174 Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol 2013 0.87
175 Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One 2012 0.87
176 Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 2011 0.87
177 Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. Regul Pept 2007 0.86
178 The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res 2010 0.86
179 Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. Int J Cancer 2012 0.86
180 Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathol 2015 0.86
181 The evolution of our understanding on glioma. Brain Pathol 2008 0.86
182 Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk Res 2010 0.85
183 Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. J Pathol 2014 0.85
184 Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007 0.85
185 Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochem Biophys Res Commun 2005 0.85
186 Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005 0.85
187 Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. Acta Neuropathol 2005 0.84
188 Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. Genes Chromosomes Cancer 2009 0.84
189 Impaired Pten expression in human malignant peripheral nerve sheath tumours. PLoS One 2012 0.84
190 Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncol 2010 0.84
191 Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. PLoS One 2013 0.83
192 Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathol 2014 0.83
193 ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013 0.83
194 Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res 2009 0.83
195 Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol 2007 0.83
196 No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Int J Cancer 2004 0.83
197 Somatic mitochondrial mutations in pilocytic astrocytoma. Cancer Genet Cytogenet 2009 0.82
198 Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes Cancer 2009 0.82
199 Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia 2014 0.82
200 Pdgfr-alpha in 1p/19q LOH oligodendrogliomas. Int J Cancer 2004 0.82
201 Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas. Acta Neuropathol 2005 0.82
202 Nbn and atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye. PLoS One 2013 0.81
203 Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathol 2014 0.81
204 Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 2005 0.81
205 Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int J Cancer 2004 0.81
206 Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monit 2004 0.81
207 Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 2014 0.80
208 No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody. Appl Immunohistochem Mol Morphol 2013 0.80
209 The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. Oncol Res 2009 0.80
210 Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology 2011 0.80
211 Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol 2010 0.79
212 Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. Histopathology 2009 0.79
213 Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Mod Pathol 2009 0.78
214 Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. J Invest Dermatol 2013 0.78
215 The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. J Perinat Med 2005 0.78
216 Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. J Mol Histol 2008 0.78
217 Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol 2012 0.77
218 Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer. Histopathology 2014 0.77
219 Mutation specific antibodies: tool or dinosaur? Oncotarget 2012 0.77
220 Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region. J Pediatr Hematol Oncol 2010 0.77
221 Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol 2005 0.77
222 Rare mutations of the DMBT1 gene in human astrocytic gliomas. Oncogene 2002 0.77
223 Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. Acta Neuropathol 2007 0.76
224 Clinical neuropathology practice news 2-2012: BRAF V600E testing. Clin Neuropathol 2012 0.76
225 Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol 2015 0.76
226 Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016 0.75
227 Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology. Pathol Res Pract 2012 0.75
228 Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. Acta Neuropathol 2014 0.75
229 Farewell to oligoastrocytoma: response to letters. Acta Neuropathol 2014 0.75
230 Occurrence of a spinal anaplastic pilocytic astrocytoma and a supratentorial PNET in an adolescent. J Pediatr Hematol Oncol 2007 0.75
231 MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Arch Dermatol Res 2014 0.75
232 No preferential loss of paternal 19q alleles in oligodendroglial tumors. Ann Neurol 2003 0.75
233 Assessment of tumor cell invasion factors in gliomatosis cerebri. J Neurooncol 2005 0.75
234 45-year-old male with symptomatic mass in the frontal lobe. Brain Pathol 2006 0.75